Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative Diseases and Ophthalmic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for OPA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OPA1 Recombinant Protein (GTPase Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View OPA1 Products |
| Gene Delivery | OPA1 Promise-ORF / Lentivirus Full-length ORF (Isoform 1) for stable cell lines. |
View OPA1 Products |
| Benchmark Ab | Anti-OPA1 Recombinant Antibody Recombinant positive control for targeting validation. |
View OPA1 Products |
| Validator | OPA1 siRNA Set For knockdown verification in mitochondrial morphology assays. |
View OPA1 Products |
| Related Target A | MFN2 Outer mitochondrial membrane fusion partner; synergistic target for mitochondrial dynamics. |
View MFN2 Products |
| Related Target B | OMA1 Metalloprotease responsible for stress-induced OPA1 cleavage; critical for off-target and pathway screening. |
View OMA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro GTPase Activity Screening | Truncated OPA1 (GTPase domain) expressed with native folding, avoiding aggregation of transmembrane regions. |
| Mitochondrial Fusion Assays | High-titer Lentivirus for stable cell line construction to monitor mitochondrial network dynamics. |
| Lack of Controls | Sequence-verified Recombinant Anti-OPA1 antibodies included as assay benchmarks. |
| False Positives | Validated siRNA pool included for target-specific knockdown verification. |
Live OPA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of OPA1 (Optic Atrophy 1) is gaining momentum, particularly in the fields of ophthalmology and neurodegeneration. As a master regulator of mitochondrial inner membrane fusion and cristae integrity, OPA1 mutations lead directly to Autosomal Dominant Optic Atrophy (ADOA). The race for OPA1 therapeutics is intensifying, with major players shifting focus from traditional gene replacement therapies to small-molecule mitochondrial kinetic modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise balance of OPA1 proteolytic processing to rescue mitochondrial dysfunction in broader indications like Parkinson's disease and myocardial ischemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lenti) | Pyrogenesis, Academic Consortia | Autosomal Dominant Optic Atrophy (ADOA) | Isoform-specific expression validation (Need sequence-verified Lentivirus) |
| Small Molecule Activators | Mitokinin, Cohbar | Parkinson's Disease, Heart Failure | GTPase enzymatic assay (Need soluble, high-purity OPA1 recombinant protein) |
| Protease Inhibitors (OMA1/YME1L) | Inhibitor-focused Biotechs | Ischemic Stroke, Mitochondrial Myopathy | Cleavage protection assays (Need wild-type OPA1 and cleavage-resistant mutants) |